Frontlight ResearchEarly access
Triple-negative breast cancer trials in United Arab Emirates
1 trial · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 2/3Not yet taking people in United Arab EmiratesA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Where
- Abu Dhabi, Al Ain City
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00